First-Line Combo for Cisplatin-Ineligible Bladder Cancer Just Misses Positive Result

(MedPage Today) -- SAN FRANCISCO -- Almost half of patients with untreated cisplatin-ineligible advanced urothelial carcinoma responded to the combination of pembrolizumab (Keytruda) and cabozantinib (Cabometyx), but that result fell short of...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news